Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

SOHO Italy 2022 and Soho Italy 2022 View overview page

2:01
The role of MRD in CLL patients with high-risk cytogenetics & future perspectives
Massimo Massaia • 25 Oct 2022
1:11
The value of using personalized approaches when treating patients with MF
Elisabetta Abruzzese • 24 Oct 2022
4:42
The role of JAK inhibitors in treating MPNs and the need for disease-modifying agents
Elisabetta Abruzzese • 24 Oct 2022
2:14
Going beyond BCMA-targeting agents in myeloma: GPRC5D and FcRH5-targeting therapies
Hans Lee • 25 Oct 2022
1:39
The growing role of MRD as a clinical endpoint in CLL
Massimo Massaia • 25 Oct 2022
1:15
The potential role of MRD in treating CLL patients receiving continuous therapy
Massimo Massaia • 25 Oct 2022
0:57
Insights into a novel antibody-drug conjugate in myeloma: HDP-101
Hans Lee • 25 Oct 2022
2:26
An insight into the aims of the Eurasian Hematology-Oncology Group
Giuseppe Saglio • 25 Oct 2022
3:20
The current standard of care in CML and insights into the use of first- and second-generation TKIs
Giuseppe Saglio • 25 Oct 2022
1:38
Using BCMA-targeting agents in earlier lines of treatment for multiple myeloma
Hans Lee • 25 Oct 2022
1:50
The possibility of using MRD status to drive treatment in AML
Alessandro Isidori • 24 Oct 2022
1:08
Insights into disease-modifying agents being explored in MPNs
Alessandro Lucchesi • 24 Oct 2022
1:24
Understanding aberrant signaling pathways to prevent resistance to JAK2 inhibitors in MPNs
Alessandro Lucchesi • 24 Oct 2022
2:29
The management of DLBCL and the importance of characterizing molecular subtypes
Gerardo Musuraca • 24 Oct 2022
3:28
The importance of BCMA-targeting ADCs and bispecific antibodies in R/R multiple myeloma
Hans Lee • 25 Oct 2022
2:13
Treatment approaches for patients with R/R AML and the importance of preventing relapse
Alessandro Isidori • 24 Oct 2022
The content of VJHemOnc is intended for healthcare professionals